ArriVent BioPharma (AVBP) Total Liabilities (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Total Liabilities data on file, last reported at $25.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 95.44% year-over-year to $25.3 million; the trailing twelve-month figure through Mar 2026 stood at $25.3 million (up 95.44% YoY), and the FY2025 full-year result was $25.9 million, up 50.08% from the prior year.
• Total Liabilities declined to $25.3 million in Q1 2026, from $25.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $25.9 million in Q4 2025 to a low of $10.1 million in Q1 2024.
• A 4-year average of $17.2 million and a median of $16.3 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities gained 28.06% in 2025 and soared 95.44% in 2026, its largest moves.
• Tracing AVBP's Total Liabilities over 4 years: stood at $11.8 million in 2023, then soared by 46.5% to $17.3 million in 2024, then soared by 50.08% to $25.9 million in 2025, then declined by 2.43% to $25.3 million in 2026.
• Business Quant data shows AVBP's Total Liabilities at $25.3 million in Q1 2026, $25.9 million in Q4 2025, and $21.6 million in Q3 2025.